|
|
| (One intermediate revision by one other user not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #redirect [[pancreatic insufficiency]] |
| {{SI}}
| |
| | |
| {{CMG}}
| |
| | |
| ==Overview==
| |
| '''Exocrine pancreatic insufficiency''' (EPI) is the inability to properly digest food due to a lack of [[digestive enzyme]]s made by the [[pancreas]]. EPI is also found in humans afflicted with [[cystic fibrosis]]. EPI is caused by a progressive loss of the pancreatic cells that make digestive enzymes. [[Chronic pancreatitis]] is the most common cause of EPI in humans .<ref name=Ettinger_1995>{{cite book|author=Ettinger, Stephen J.;Feldman, Edward C.|title=Textbook of Veterinary Internal Medicine|edition=4th ed.|publisher=W.B. Saunders Company|year=1995|id=ISBN 0-7216-6795-3}}</ref> Loss of digestive enzymes leads to [[maldigestion]] and [[malabsorption]] of nutrients.
| |
| | |
| ==Causes==
| |
| In humans, the common causes of EPI are [[Cystic Fibrosis]], which is a hereditary recessive disease of Europeans and Ashkenazi Jews involving the [[ion channel|sodium-chloride channel]]s, and [[chronic pancreatitis]].
| |
| | |
| ==Treatment==
| |
| Often this is treated with Pancreatic Enzyme Products (PEPs), such as [[pancrelipase]], that are used to breakdown fats ([[lipases]]), proteins ([[proteases]]) and carbohydrates ([[amylases]]) into units that can be digested by those with EPI. <ref>[http://www.fda.gov/cder/otcmonographs/category_sort/pancreatic_insufficiency.htm FDA rulemaking history of OTC EPI drug products]</ref>
| |
| | |
| ==References==
| |
| {{Reflist|2}}
| |
| | |
| | |
| [[de:Exokrine Pankreasinsuffizienz]]
| |
| [[ja:膵外分泌不全]]
| |
| | |
| {{WH}}
| |
| {{WS}}
| |